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Abstract

Aims Cholesterol plays an essential role in membrane structure and function, being especially important in
the brain. Alteration of brain cholesterol synthesis and metabolism has been demonstrated in several
Huntington's disease (HD) mouse and cell models; however, less is known about these alterations in human
tissue. This study aimed to identify alterations to cholesterol synthetic and metabolic pathways in human HD
brain tissue. Methods A broad range of cholesterol synthetic precursors, metabolites and oxidation products
were measured by gas chromatography-tandem mass spectrometry in five regions of human post mortem HD
brain and compared with age- and sex-matched control tissues. The level of enzymes that regulate cholesterol
homeostasis, cholesterol 24-hydroxylase and delta(24)-sterol reductase were investigated by Western blotting
and qPCR in putamen. Results The most significant changes were localized to the putamen, where a 60%
decrease in 24(S)-hydroxycholesterol, 30% increase in cholesterol and 100-200% increase in synthetic
precursors (lathosterol, zymosterol and desmosterol) was detected. The enzymes cholesterol 24-hydroxylase
and delta(24)-sterol reductase were also significantly decreased in HD putamen as compared with control
tissues. Free radical-generated cholesterol oxidation products 7-keto cholesterol and 7β-hydroxycholesterol
were also increased by 50-70% in HD putamen. Conclusion Human HD brain has significantly decreased
cholesterol metabolism and disrupted cholesterol homeostasis. Our data also indicate that lipid oxidative
stress accompanies HD pathology.
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Abstract

Aims: Cholesterol plays an essential role in membrane structure and function, being
especially important in the brain. Alteration of brain cholesterol synthesis and metabolism
has been demonstrated in several Huntington’s disease (HD) mouse and cell models, however
less is known about these alterations in human tissue. This study aimed to identify alterations
to cholesterol synthetic and metabolic pathways in human HD brain tissue.
Methods: A broad range of cholesterol synthetic precursors, metabolites and oxidation
products were measured by GC-MS/MS in five regions of human post-mortem HD brain and
compared to age- and sex-matched control tissues. The level of enzymes that regulate
cholesterol homeostasis, cholesterol 24-hydroxylase and delta(24)-sterol reductase were
investigated by Western blotting and qPCR in putamen.
Results: The most significant changes were localised to the putamen, where a 60% decrease
in 24(S)-hydroxycholesterol, 30% increase in cholesterol and 100 to 200% increase in
synthetic precursors (lathosterol, zymosterol and desmosterol) was detected. The enzymes
cholesterol 24-hydroxylase and delta(24)-sterol reductase were also significantly decreased in
HD putamen as compared to control tissues. Free radical-generated cholesterol oxidation
products 7-keto cholesterol and 7β-hydroxycholesterol were also increased by 50 to 70% in
HD putamen.
Conclusion: Human HD brain has significantly decreased cholesterol metabolism and
disrupted cholesterol homeostasis. Our data also indicates that lipid oxidative stress
accompanies HD pathology.
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Abbreviations:
HD = Huntington’ disease, GC-MS = gas chromatography-mass spectrometry, HTT =
huntingtin, DHCR24 = delta(24)-sterol reductase, BBB = blood brain barrier, 24-OHC =
24(S)-hydroxycholesterol, CYP46A1 = cholesterol 24-hydroxylase, 27-OHC = 27hydroxycholesterol, CYP27A1 = cholesterol 27-hydroxylase, CYP7B1 = 5hydroxycholesterol 7-α-hydroxylase, AD= Alzheimer’s disease, PD = Parkinson’s disease,
ROS = reactive oxygen species, COPs = cholesterol oxidation products, 7β-OH = 7βhydroxycholesterol, 7-KC = 7-ketocholesterol, BDNF = brain derived neurotrophic factor.

Introduction
Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative disease
characterised by the expansion of a glutamine repeat on the N-terminus of the huntingtin
protein (HTT). Classic symptoms include involuntary movement and cognitive dysfunction.
The classical neuropathological hallmark of HD is the severe atrophy of the striatum (caudate
and putamen) [1], with substantial volume loss in the order of 50%. While these brain regions
are most severely affected, MRI techniques have highlighted that the hippocampus, cerebral
cortex, globus pallidus and amygdala also have reduced volume in HD patients [2]. Loss of
neurons is accompanied by progressive astrocytosis and an increased density of
oligodendrocytes [3]. While it is not fully understood how the polyglutamine expansion
causes cellular dysfunction in HD, it has been associated with lipids, altering membrane order
[4] and the interaction with phospholipids [5]. Despite the genotypic identification of mutant
huntingtin carriers, there is a lack of reliable biomarkers to predict HD progression or
effectiveness of therapies. Several studies have identified that cholesterol synthesis and
metabolism in HD cell lines and animal models is significantly disturbed [6-8], but the
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mechanisms and metabolic pathways affected have not been fully examined in human HD
brain.

Cholesterol is highly concentrated in the brain, accounting for 25% of total body cholesterol.
The majority of cholesterol is found in myelin, accounting for 70% of total cholesterol, with
the remainder found in cellular membranes of neurons and glial cells. Cholesterol has an
essential role in many neurological processes including synaptogenesis [9], axon growth [10]
and maintenance of dendrites [11]. Structurally, cholesterol modulates membrane fluidity and
organisation [12] where it can alter signalling functions, membrane protein organisation and
lipid raft structure [13-16]. Brain levels of cholesterol are tightly regulated by de novo
synthesis, a pathway that involves over 20 steps. In the late stage of cholesterol synthesis the
pathway branches at lanosterol into the Bloch pathway via the precursor desmosterol, or the
Kandutsch-Russell pathway via lathosterol. Several other post squalene precursors exist in
these pathways (see Fig. 1). Plasma levels of synthetic precursors have been positively
correlated to whole body cholesterol synthesis [17, 18], but this does not reflect cholesterol
synthesis in the central nervous system. Direct measurement of precursor levels in brain
tissue is therefore necessary to monitor the cholesterol synthetic pathway [7, 8, 19]. Defects
in the cholesterol synthetic pathway can have severe consequences, especially in the brain
where tight regulation of cholesterol synthesis is essential for normal neuronal function.
Mutations in downstream synthetic enzymes such as delta(24)-sterol reductase (DHCR24)
can cause desmosterolosis [20], a severe developmental and neurological disorder.
The blood brain barrier (BBB) is impermeable to cholesterol, preventing fluctuations in
circulating cholesterol affecting brain levels. The hydroxylation of cholesterol to more polar
oxysterols enables movement across the BBB. 24(S)-Hydroxycholesterol (24-OHC), formed
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by the brain specific enzyme cholesterol 24-hydroxylase (CYP46A1) has been identified as
the major route of cholesterol elimination from the human brain [21]. Since CYP46A1
expression is primarily localised to neurons [22], it has been suggested that generation of 24OHC (as measured in plasma) is a marker of metabolically active neurons in the brain [23].
Plasma 24-OHC levels are reduced in HD patients [24, 25] and recent evidence suggests that
changes in CYP46A1 and 24-OHC brain levels may play a role in neurodegeneration [26-29].
However, the exact role this might play in HD pathogenesis has not been established.
Oxysterols formed in peripheral tissue may also enter the brain. C27 hydroxylation of
cholesterol forms 27-hydroxycholesterol (27-OHC), an enzymatic reaction that occurs in
many tissues outside the central nervous system. A concentration gradient results in a net
movement of 27-OHC from circulation into the brain [30], where it is quickly metabolised
into more polar products (including dihydroxysterols and cholestenoic acids), catalysed by
the enzymes cholesterol 27-hydroxylase (CYP27A1) and 5-hydroxycholesterol 7-αhydroxylase (CYP7B1) [31]. Accumulation of 27-OHC has been described in cases of
Alzheimer’s disease (AD) [32] as well as patients with hereditary defects in the CYP7B1 gene
[33], but very little is known regarding 27-OHC changes in HD.
Accumulation of unrepaired oxidative damage to biological macro molecules is a major
component of neurodegenerative diseases, including AD [34] and Parkinson’s disease (PD)
[35]. Oxidative stress is also observed in HD with markers of lipid peroxidation and DNA
oxidation elevated [36-38]. Brain lipids represent a major target for oxidation, particularly
cell membrane cholesterol that is susceptible to reactive oxygen species (ROS) attack and
formation of cholesterol oxidation products (COPs). 7β-Hydroxycholesterol (7β-OHC) and 7ketocholesterol (7-KC) are formed by direct ROS attack at the 5,6 double bond on
cholesterol, and are elevated in diseases and pathological models that involve oxidative stress
including atherosclerosis [39, 40], cystic fibrosis [41] and retinal photodamage [42]. Due to
5

the large pool of cholesterol in the brain, COPs represent potentially important biomarkers for
neurodegenerative diseases.
Perturbed cholesterol pathways have been previously reported in HD mouse and cell models
[6, 7, 19, 43]. While these models have described significant alteration of cholesterol
synthesis and metabolism, the current literature contains very limited data obtained from
human tissue, which is required for greater understanding of human HD pathophysiology.
Here we report for the first time the level of cholesterol metabolites, synthetic precursors and
oxidation products in 13 cases of human HD across 5 brain regions. We have also
investigated the levels of two key cholesterol synthetic and metabolic enzymes in HD
putamen.
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Materials and Methods
Materials
Desmosterol-d6, zymosterol-d5, zymosterol and lanosterol-d6 were obtained from Avanti
lipids (Alabaster, AL, USA). Tert- butylhydroxytoluene (BHT), cholesterol, -cholestane,
7–hydroxycholesterol, 7-dehydrocholesterol and 7-ketocholesterol and squalene were from
Sigma (St. Louis, MO, USA). Lathosterol, lanosterol, desmosterol, 27-hydroxycholesterol,
campesterol, and were obtained from Steraloids (Newport, RI, USA). Campesterol-d3, 7–
hydroxycholesterol-d7, lathosterol-d4 and 7-ketocholesterol-d7 were purchased from CDN
Isotopes (Quebec, Canada). 27-hydroxycholesterol-d5, 24-hydroxycholesterol and 24hydroxycholestero-d7 were from Medical Isotopes , Inc (Pelham, AL, USA). Squalene-d6 and
24,25-dihydrolanosterol-d6 was obtained from Toronto research chemicals (TRC, Ontario,
Canada). All standards obtained were of the highest purity (>95%). Methanol, hexane,
methyl tert-butyl ether (MTBE), acetonitrile, toluene, formic acid and NaOH were purchased
from Ajax Finechem (Thermo Fisher Scientific, AU). CUQAX223 UCT Clean-Up QAX2
solid phase extraction columns and BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) +
1% TMCS (trimethylchlorosilane) was purchased from PM Separations (Qld, Australia).

Human brain tissue
Frozen brain tissues from five brain regions (putamen, caudate, cerebellum, grey and white
frontal cortex) were received from the Victorian Brain Bank Network. The cohort contained
13 cases of HD and 13 controls from each brain region. Tissue was transported on dry ice and
stored at -80°C until analysis. Demographic and basic clinical data are presented in Table 1.
The mean age of control cases was 68.9 ± 1.9 y which was not significantly different from
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the HD cases with mean age of 67.3 ± 2.2 y. Post mortem interval (PMI) of control cases
(41.5 ± 4 h) and tissue pH (6.4 ± 0.1) was not significantly different to HD PMI (37.5 ± 6.2
h) or tissue pH (6.4 ± 0.04). All brain tissue was from the left hemisphere of Caucasian
donors. Ethics approval was from the University of Wollongong Human Research Ethics
Committee (HE10/327). Control tissue was screened using standardized protocols to confirm
the absence of degenerative pathologies. The research was carried out in accordance with the
Declaration of Helsinki (2008) of the World Medical Association. All persons gave their
informed consent prior to their inclusion in the study.

Lipid extraction
Brain lipids were extracted as previously described with minor modifications [44]. Frozen
brain tissue (~5-10 mg) was weighed directly into a 0.5 mL polypropylene tube containing 5
Zircosil® ceramic beads (1.3 mm) (Klausen Pty Ltd, NSW, Australia), 150 µL methanol
(0.01% BHT) and internal standards (4oC). Tissue was homogenised at 4°C using a Precellys
24 homogeniser (Bertin Technologies) (2 x 20 s at 5,000 rpm) and the homogenate was
transferred to a clean glass vial. The tube and ceramic beads were washed with 100 µL
methanol (4°C) and was added to the homogenate with 250 µL of NaOH (1 M). The sample
was hydrolysed at room temperature for 16 h in the absence of light and then acidified with
330 µL of 1 M formic acid. The sample was made up to a final volume of 3 mL (8%
methanol, pH 4.5) by the addition of 2.2 mL milliQ water. Solid-phase extraction (SPE) was
carried out on a 200 mg mixed C8/anion exchange quaternary amine column (CUQAX223,
UCT Inc.) that had been preconditioned with 2 mL methanol and then 2 mL 40 mM formic
acid buffer (pH 4.5). The lipid extract was loaded and the column washed with 2 mL
methanol in 40 mM formic acid (40:60). The SPE column was dried with N2 gas flow for 5
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min. Sterols and oxysterols were eluted with 2 mL hexane followed by 2 mL hexane/MTBE
(50:50).

GC-MS sterol analysis
GC-MS sterol analysis was performed as previously described with minor modifications [35].
The sterol/oxysterol fraction was dried under N2 at 37°C and derivatised by the addition of 20
µL acetonitrile and 20 µL BSTFA + 1% TMCS for one hour at 37oC. Samples were dried
under N2 and immediately reconstituted in 40 µL toluene for GC-MS/MS analysis. Selective
reaction monitoring (SRM) analysis of sterols/oxysterols was carried out on an Agilent
7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC system
gas chromatograph. Quantification was performed by Agilent Masshunter Quantitative
software (V B.05.00) by comparison of specific SRM transitions with their heavy isotopes
and using relative response factor (RRF) calibration. Cholesterol was quantified using the
internal standard α-cholestane in a separate injection and chromatographic run.

Western Blotting
Brain tissue (~20 mg) was added to 250 uL ice cold radio-immunoprecipitation assay (RIPA;
50 mM Tris, 150 nM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 100) buffer
containing 1% protease inhibitor (P8340, Sigma) and homogenised at 4°C using a Precellys
24 homogeniser (Bertin Technologies) (2 x 20 s, 6000 rpm). The homogenate was
centrifuged at 14 000 x g and the soluble fraction taken for SDS-PAGE. Homogenates were
incubated at 95°C for 10 min with loading dye containing β-mercaptoethanol. Equal amounts
of protein (90 µg) were loaded onto a 12% acrylamide gel and electrophoresed for 1 h at
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150V. Proteins were then transferred onto a 0.4 µm nitrocellulose membrane (BIO-RAD,
Gladesville, NSW, Australia) for 35 min at 100V. Antigen retrieval was performed by adding
50 mL of boiling phosphate buffered saline + tween 20 (PBST) to the membrane and left to
cool to room temperature. The membrane was blocked with a 10 mL solution of PBST
containing 5% skim milk powder, rocking for 1 h at room temperature. Membranes were
probed with antibodies detecting CYP46A1 1:100 (1F11, Santa Cruz Biotechnology) and
DHCR24 1:1000 (ab137845, Abcam). Antibodies were diluted in 10 mL PBST 5% skim milk
powder and incubated with membranes overnight, rocking at 4°C. Membranes were washed 3
x 10 min with PBST at room temperature before being incubated for 1 h at room temperature
with a species specific IgG-HRP conjugated secondary antibody (1:3000). Membranes were
washed 3 x 10 min with PBST before chemiluminescent detection of signal. Membranes were
stripped, washed and re-probe for β-actin (1:10 000) following the protocol outlined above.
Signal intensity was quantified using ImageJ software V1.46r (National Institutes of Health,
USA), and normalised for β-actin.

qPCR
The quantitative PCR of human brain tissue was performed as previously described [45] with
minor modifications. Briefly, human tissue (~30mg) was added to 10 volumes of TRIzol
reagent (wt:vol) and homogenised in a Precellys 24 homogeniser at 2 x 20 s at 5500 rpm. The
RNA concentration and purity was determined spectrophotometrically with a Nanodrop 1000
(Thermo Scientific). Following the manufacturer’s protocol, 2 µg of total RNA was used to
synthesise cDNA using a Tetro cDNA synthesis kit (Oligo dT18) (Bioline, Sydney, Australia).
Quantitative PCR was performed using a Roche Lightcycler 480 using SensiFAST SYBR
No-ROX kit (Bioline) following the manufacturer’s instructions. Analyses were carried out in
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triplicate and gene of interest mRNA was normalised to GAPDH and U6 mRNA levels. Gene
expression was calculated using the comparative threshold cycle (Ct) value method using the
formula 2-ΔΔCt (ΔΔCt = ΔCt sample – ΔCt reference) as described [46]. All primers were
purchased from Sigma Aldrich (Sydney, Australia). The primer sequences used are as
follows:

CYP46A1

(F:

TTCTAGGACACCTCCCCTGC

and

R:

CAGGTCCATACTTCTTAGCCCAAT) DHCR24 (F: TGTTCGTGTGCCTCTTCCTC and
R: ATTCCCGCACCTGCTTCTG) GAPDH (F: GAGCACAAGAGGAAGAGAGAGACCC
and

R:

GTTGAGCACAGGGTACTTTATTGATGGTACATG)

U6

(F:

CTCGCTTCGGCAGCACA and R: AACGCTTCACGAATTTGCGT).

Statistical analysis
Statistical analyses were performed using GraphPad Prism software V5.00 (Graphpad
Software Inc., USA). An unpaired t-test was used to test for significantly different means, an
F-test was used to determine if variances were significantly different. Welch’s correction for
unequal variances was used when variances were found to be significantly different.
Additional post hoc adjustments for multiple comparisons were conducted using the
Benjamini and Hochberg method [47] in JMP software V12.1.0 (SAS Institute Inc., USA).
All results are expressed as mean ± SEM with an adjusted P < 0.05 considered significant. A
full list of P-values and adjusted P-values can be found in Supplemental Table 1.

Results
Human HD post mortem brain tissue from putamen, caudate, frontal cortex (grey and white)
and cerebellum was analysed using mass dilution GC-MS/MS. Cholesterol metabolites,
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oxidation products and synthetic precursors are presented as percent relative change
compared to control (Fig. 2). Absolute values of sterols measured are provided in
Supplemental Table 2.

Cholesterol metabolites
The most significant changes were detected in HD putamen, a region that is severely affected
in HD. The brain specific cholesterol metabolite 24-OHC, was reduced close to 3-fold (p =
0.0011) in HD putamen (Fig. 2A). Caudate was the only other region to show changes in this
metabolite with a 3-fold reduction (p = 0.0099) of 24-OHC in HD tissue compared to control
tissue (Fig. 2A). 27-OHC, a peripheral cholesterol metabolite was significantly increased by
3-fold in HD putamen (p = 0.0196).
Cholesterol oxidation products
HD putamen was the only brain region to show evidence of oxidative stress, with a 50 to 70%
increase in the cholesterol oxidation products 7-KC (p = 0.00495) and 7β-OH (p = 0.0355)
(Fig. 2B).

Cholesterol synthetic precursors
Altered cholesterol synthesis was evident in HD putamen which exhibited increases in the
cholesterol synthetic precursors, desmosterol (3-fold, p = 0.0140), lathosterol (2-fold, p =
0.0495), zymosterol (3-fold, p = 0.0145) and 24, 25 dihydro lanosterol (2-fold, p = 0.0140)
(Fig 2C). Total cholesterol levels were also significantly increased by 30% in HD putamen (p
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= 0.0470) (Fig. 2D). No other brain regions were found to have significant changes in
cholesterol precursors, or cholesterol levels.

Metabolic and synthetic enzymes
To further investigate pathways that may contribute to changes in brain cholesterol
metabolism and synthesis observed in putamen, we examined two major enzymes involved
by western blotting. The protein level of CYP46A1 in HD was reduced 10-fold compared to
control (p = 0.0027) (Fig. 3A). We also detected a significant (10-fold) reduction (p =
0.0014) of DHCR24 protein levels (Fig. 3B), which is in agreement with the accumulation of
desmosterol seen in HD putamen (Fig. 2B).
The mRNA levels of the genes coding for cholesterol 24-hydroxylase (CYP46A1) and
delta(24)-sterol reductase (DHCR24) were also measured in putamen using quantitative PCR.
mRNA levels did not reflect protein levels and were not significantly changed between HD
and control tissue in both CYP46A1 and DHCR2 (Fig. 4). mRNA levels normalised to
individual house keeper genes can be found in Supplemental Figure 1.
Discussion
Alteration of cholesterol metabolism has been recently linked to several neurodegenerative
diseases including AD, PD and HD [35, 43, 48]. In particular, the elimination pathway where
24-OHC is formed by the hydroxylation of cholesterol has been suggested as a contributing
factor in neurodegeneration [49]. Neuronal 24-OHC has a major role in the turn-over of
cholesterol in the brain [21], and the level of 24-OHC in plasma has been suggested as a
measure of CYP46A1 enzymatic activity and thus metabolically active neurons [23].
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Previous studies have found that the plasma levels of 24-OHC in HD patients correlate with
disease severity and brain volume measured by MRI [24, 25]. Here for the first time we
report the levels of 24-OHC in human HD post-mortem brain tissue. A significant reduction
of 24-OHC was found in HD putamen along with a large (10-fold) reduction in the protein
level of CYP46A1, the enzyme responsible for 24-OHC formation. Reduced enzyme levels
may be due to neuronal loss, the location which CYP46A1 is primarily located. Alterations in
post-transcriptional regulation may also play a role since no change in mRNA expression was
detected between control and HD. This is potentially relevant as protein turnover is known to
be dysregulated in HD cell models [50]. Caudate (another striatal region affected in HD) also
had reduced levels of 24-OHC, while grey and white frontal cortex and cerebellum showed
no change. Although the cerebral cortex is affected in later stages of HD [2, 51], the degree of
volume loss and astrocytosis is substantially less compared to the striatum [2, 52, 53].
Reduced 24-OHC levels in HD striatum supports previous human studies that reported
reduced plasma levels of this metabolite in HD patients [24, 25]. Our data indicates that
decreased circulating 24-OHC levels are likely the result of reduced 24-OHC production in
affected regions and not an aberration of BBB 24-OHC flux. In the mature brain, delivery of
cholesterol synthesised in the astrocyte is required for normal neuronal function [9, 10, 54].
It has been hypothesised that 24-OHC production in neurons acts as a feedback molecule to
initiate the delivery of cholesterol from astrocytes to neurons therefore maintaining
homeostasis [55]. There is also evidence to suggest that CYP46A1 may have neuroprotective
properties, being upregulated near plaques [27] and in glia of human AD brain [56]. Whether
reduced levels of CYP46A1 in HD is a secondary event reflecting active neuron loss, or is a
pathogenic factor altering cholesterol metabolism and synthesis remains to be established.
A defect in cholesterol synthesis has been previously described in several cell and mouse
models of HD. Specifically; a reduction in the cholesterol synthetic precursors lathosterol and
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lanosterol as well as cholesterol in the YAC128 mouse [19], reduced levels of lathosterol and
lanosterol but not cholesterol in the R6/2 mouse model [7], reduced mRNA levels of
cholesterol synthetic enzymes in R6/2 mouse and human HD fibroblasts [6] and reduced
cholesterol synthetic enzymes in a transgenic HD cell model [43]. In contrast to these
findings, our data in end stage human HD putamen describes an increase in cholesterol
synthetic precursors from both the Bloch (desmosterol and 24,25 diHydro lanosterol) and
Kandutsch-Russell (lathosterol and zymosterol) pathways and an increase in total cholesterol
levels. No significant changes in squalene levels were observed (Suppl. Table 2) suggesting
that the earlier mevalonate pathway did not influence the changes that we measured later in
the pathway. The increase in cholesterol and synthetic precursors was only observed in the
putamen; a region that degenerates early and severely in the human disease [57]. In contrast
to macro and microscopic classification of disease pathology which sees the caudate
degenerate consistently with the putamen [53, 57], we did not observe any cholesterol
synthetic alterations in this region. While the cholesterol synthetic changes observed in the
putamen may suggest an overall increase of cholesterol synthesis utilising both pathways, we
believe this is not the case for the Bloch pathway. In our study, HD putamen had significantly
higher levels of desmosterol, an immediate synthetic precursor of cholesterol and a substrate
of DHCR24. Significantly depleted protein levels of DHCR24 in human HD putamen (10fold) provides convincing evidence to explain the reduced DHCR24 activity and subsequent
accumulation of desmosterol. Unaltered mRNA levels of DHCR24 in putamen again suggests
enzyme levels are being affected post-transcription. Previous in vitro examination of
cholesterol synthesis in specific cell types found astrocytes utilise the Bloch pathway via
desmosterol, while neurons primarily utilised 7-dehydro cholesterol and other precursors
from the Kandutsch-Russell pathway [58]. This suggests that in late stage human HD,
desmosterol accumulates in astrocytes due to down regulated DHCR24. An increased density
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of oligodendrocytes and activated astrocytes is known to be present in HD [3] and is believed
to be a compensatory response to demyelination in HD [59]. While the specific cell type/s
exhibiting elevated Kandutsch-Russell synthetic precursors is yet to be determined, increased
oligodendrocytes attempting remyelination in affected tissue may contribute to this.

Previous studies in HD mouse brain reported a significant reduction of the cholesterol
precursor lathosterol, which is found in the Kandutsch-Russell pathway. In contrast, the
Bloch pathway precursor desmosterol, was either unchanged [19] or not reported [7] in these
previous HD mouse studies. Examining precursors from both arms of the cholesterol
synthetic pathway in these mouse models enables greater insight into the alterations occurring
in different cell types, and their possible response to HD pathology / neurodegeneration. The
differences seen between HD mouse models, in vitro cell models, and human post-mortem
tissue may reflect a difference in the homeostatic response to mutant HTT between organisms
and cell types. The differences in the data derived from our current study and previous mouse
models and cell culture models may also reflect that in this study we examined end stage HD
where a significant number of vulnerable neurons are predicted to have been lost. Examining
earlier stages of the disease in brain tissue is therefore important to consolidate the role of
cholesterol synthesis and metabolism in the early stages of HD in humans.

27-Hydroxycholesterol, a metabolite of cholesterol that is produced predominantly in
peripheral tissue, was increased in the putamen of human HD brain as compared to controls.
A trending increase was observed in grey cortex and cerebellum; however this lost
significance after P-value adjustment. While an increased flux of 27-OHC into the brain may
be caused by a disrupted BBB, we believe this is not the case in this tissue since sterols that
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are present in higher peripheral abundance such as campesterol (a dietary derived
phytosterol) were not significantly different between HD and control brain tissues (data not
shown). As there is a net movement of 27-OHC from circulation into the brain [30], 27-OHC
accumulation may be the result of a decrease in the activity of enzymes (such as CYP27A1)
that further metabolises this oxysterol to cholestenoic acids [31]. Accumulation of 27-OHC is
potentially important in neurodegeneration as in vitro studies have shown 27-OHC promotes
β-amyloidogenesis [60] as well as being elevated in human AD brain and transgenic mice
[32, 61]. While there is little direct in vivo physiological evidence that cholesterol metabolites
promote neuronal damage, further studies are required to investigate the hypothesis that
preventing the accumulation of 27-OHC in the brain reduces neurodegeneration in AD and
HD.

Along with measuring cholesterol metabolites and precursors, our GC-MS method was able
to sensitively detect oxidation products of cholesterol, and use these as markers of oxidative
stress in HD brain tissue. Oxidative stress has been previously shown in HD [36], and in
several other neurodegenerative diseases [34, 35, 62]. Similar to changes seen in other
sterols, significant increases in 7-KC and 7β-OH were only observed in putamen. The
specific increase in oxidation products in the putamen is consistent with this region being
affected early and severely in HD [57]. 7-KC and 7β-OH have been shown to be stable, and
previously used as markers of oxidative stress in plasma [40] and CSF [63]. Measurement of
cholesterol oxidation in HD plasma together with other sterols may represent a convenient
tool to follow progression, quantify severity, and assess therapeutic effectiveness in patients.
Importantly, these markers can be measured sensitively and reliably by GC-MS techniques.
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Homeostasis of cholesterol is essential for neurological function however the precise role of
cholesterol in HD neurodegeneration is still debated. Evidence suggests that cholesterol
accumulation in HD alters membrane organisation and cell signalling, enhancing the
susceptibility of striatal neurons to excitotoxicity [4]. Another hypothesis suggests that
impaired cholesterol synthesis drives neurodegeneration by limiting the supply of cholesterol
to neurons [19]. As a result synaptogenesis and dendrite outgrowth is impaired [9, 11], and
neurotransmission is disrupted [64]. It is also believed that a reduction of brain derived
neurotrophic factor (BDNF) in HD [65] may play a significant role in neurodegeneration
[66]. BDNF is a neurotrophin expressed by neurons which promotes cell survival,
differentiation and growth [67]. Among these properties, BDNF has been shown to promote
DHCR24 expression [68]. Therefore, a loss of BDNF action may also contribute to the
cholesterol homeostatic imbalance we have detected in HD putamen.
Our study identifies for the first time that several cholesterol synthetic and metabolic
pathways are disturbed in multiple brain regions of human HD, particularly putamen which
plays a central role in HD pathophysiology. These data provide evidence to support previous
studies that link altered cholesterol synthesis, metabolism and oxidative stress with the
neuropathological process involved in HD. Since HD shares similar sterol disturbances as
other late-onset neurodegenerative diseases, we believe these changes represent potential
biomarkers for neurodegenerative disease and elucidating cholesterol related mechanisms of
neuropathology may provide targets for therapeutic intervention. The key finding of reduced
CYP46A1 in human HD brain confirms previous studies in HD patient plasma that indicate
24-OHC as a promising peripheral biomarker to monitor the development of HD
neuropathology.
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Figure legends
Fig. 1 Simplified pathway showing cholesterol synthesis, metabolism and free radical
oxidation relevant to this study. Major post squalene cholesterol synthetic precursors shown
follow a branched pathway, the Kandutsch-Russell pathway or Bloch pathway. Cholesterol
can be oxidised enzymatically to form 24(S)-hydroxycholesterol (24-OHC) or 27hydroxycholesterol (27-OHC) by cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27hydroxylase (CYP27A1). Reactive oxygen species (ROS) can oxidise cholesterol to form 7ketocholesterol and 7β-hydroxycholesterol. The position of delta(24)-sterol reductase
(DHCR24), a cholesterol synthetic enzyme is also shown. Broken lines indicate intermediates
that have not been shown in this simplified scheme
Fig. 2 Sterol levels in human HD putamen, caudate, grey cortex, white cortex and
cerebellum. (A) Cholesterol metabolites (B) Cholesterol oxidation products (C) Cholesterol
synthetic precursors (D) Cholesterol were measured by GC-MS/MS. Levels are expressed as
a percentage change against control tissue. n = 12-13 per group, error bars represent +SEM
**p < 0.005, *p < 0.05
Fig. 3 Protein level of cholesterol synthetic and metabolic enzymes in human putamen. Brain
tissue homogenates from HD and control were probed for (A) cholesterol 24-hydroxylase
(CYP46A1)

and

(B)

delta(24)-sterol

reductase

(DHCR24)

by

western

blotting.

Representative blots are shown (n = 3 per group). Integrated optical density for all blots (n =
9 per group) is represented as relative abundance compared to control (assigned a value of
1.0). Blots were normalised to β-actin level. Error bars represent +SEM. **p < 0.005
Fig. 4 mRNA levels of genes coding for cholesterol synthetic and metabolic enzymes in
human putamen. The level of CYP46A1 (coding for cholesterol 24-hydroxylase) and
DHCR24 (coding for delta(24)-sterol reductase) in brain tissue was determined by qPCR (n =

24

9 for control and HD). The genes of interest were normalised to GAPDH and U6 mRNA
levels and expressed relative to control (assigned a value of 1.0). Error bars represent +SEM
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